Report

Moderna’s personalized mRNA cancer vaccine reportedly gets positive phase 3 results; efficacy figures expected October 24

A Substack writer says the announcement gave no efficacy numbers, while Moderna’s stock rose 177 percent.

1 Source, 20d ago, first seen 20d ago

TLDR

A Substack writer says Moderna’s personalized mRNA cancer vaccine had a positive phase 3 result, but the announcement disclosed no efficacy numbers. The writer says Moderna’s stock rose 177 percent and expects the figures at ESMO on October 24, 2026.

Today's Rank

—

Not ranked yet

Combined views

1 Source, first seen 20d ago

Sentiment

Positive——Negative

Summary

Not enough discussion yet.

No sentiment analysis available yet.

Featured Source